News Releases

Company to Hold Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 30, 2020 SEATTLE --(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and

SEATTLE --(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40 th Annual Healthcare Conference scheduled for Tuesday, March 3, 2020 at 11:20 am. Eastern Time .

SEATTLE --(BUSINESS WIRE)--Feb. 25, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at two upcoming investor healthcare conferences in March.

SEATTLE --(BUSINESS WIRE)--Jan. 24, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented new preclinical data on its lead autoimmune/inflammatory

SEATTLE --(BUSINESS WIRE)--Jan. 6, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohn’s &

ALPN-101 demonstrates ability to potently inhibit both T and B cell responses in first-in-human study Human experience supports both IV and SQ dosing regimens SEATTLE --(BUSINESS WIRE)--Dec. 9, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused

SEATTLE --(BUSINESS WIRE)--Nov. 26, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced participation in an analyst-led fireside chat at

Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE) Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020 Conference Call Scheduled for 4:30 p.m. ET Today SEATTLE --(BUSINESS WIRE)--Nov.

ALPN-101 is distinct from the other biologic therapies and superior to combination biological blockade Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory diseases SEATTLE --(BUSINESS WIRE)--Nov. 12, 2019-- Alpine Immune Sciences, Inc.

  Preclinical data support unique mechanism of action of ALPN-202 as a first in class conditional CD28 Agonist ALPN-202 able to increase CD8+ T-cells in tumors ALPN-202 has potent monotherapy activity and significantly improves upon the activity of multiple anticancer therapies in preclinical